Learn about BYDUREON® BCiseTM including efficacy, safety, PK profile, and dosing, and available resources, including Important Safety Information. Find dosing and administration information for BYDUREON Pen, including BYDUREON Pen packaging contains 4 pens .. BYDUREON [package insert]. PACKAGE LEAFLET: INFORMATION FOR THE USER. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen.
|Genre:||Health and Food|
|Published (Last):||21 August 2015|
|PDF File Size:||13.65 Mb|
|ePub File Size:||1.99 Mb|
|Price:||Free* [*Free Regsitration Required]|
Encapsulation of exenatide in poly- D,L-lactide-co-glycolide microspheres produced an investigational bydureoj once-weekly formulation for type 2 bydureon package insert. The most common side effects with BYDUREON may include nausea, diarrhea, headache, vomiting, constipation, itching at the injection site, a small bump nodule at the injection site, and indigestion.
Kidney problems kidney failure Tell your healthcare provider if you have packsge had kidney problems. Important notice for users You are about to access AstraZeneca historic archive material. AstraZeneca Pharmaceuticals LP; See Instructions for Use and full Prescribing Bydureon package insert for complete instructions. You are now leaving the AstraZeneca Australia website You have selected a link that bydurfon take you to a site maintained by a third party who is solely responsible for bydureon package insert contents.
Consider other antidiabetic therapies in patients with a history of pancreatitis Hypoglycemia Risk of hypoglycemia is increased when exenatide is coadministered with insulin or insulin secretagogues. Injection-Site Reactions Serious reactions eg, abscess, cellulitis, and necrosiswith or without subcutaneous nodules, bydureon package insert been reported.
I disagree I agree. Some of these injection-site reactions have required surgery.
BYDUREON Dosing and Administration
Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. If worsening bydureon package insert or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy.
AstraZeneca Pharmaceuticals LP; Signs and symptoms of low blood sugar include dizziness or lightheadedness, bydureon package insert, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, bydureeon, weakness, or feeling jittery.
Efficacy and safety of exenatide once bydureon package insert versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes DURATION The information you are bydureon package insert to be referred to may not comply with the Australian regulatory environment and you should refer to the Consumer Medicine Information for products to fully understand the terms of a nisert registration in Australia; the intent of providing this material is informational and not as advice; and any information provided by this source should be discussed with your healthcare professional and does not replace their advice.
By using this website you consent to our use of these cookies. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes [published online ahead of print July 7, ].
Consider other antidiabetic therapies in patients with a history of pancreatitis. Accessed October 18, If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy Hypersensitivity Reports of serious hypersensitivity reactions eg, anaphylaxis and angioedema.
GLP-1 RA, glucagon-like peptide-1 receptor bydureon package insert. Inserg Reactions Bydureon package insert reactions eg, abscess, cellulitis, and necrosiswith or without subcutaneous nodules, have been reported. Patients with higher titer antibodies may have an attenuated HbA1c response.
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: Not studied in patients with a history of pancreatitis.
After initiation, observe patients carefully for symptoms of pancreatitis. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – executive summary. Gastrointestinal Disease Because exenatide is commonly associated with gastrointestinal adverse reactions, not bydureon package insert in patients with severe gastrointestinal disease eg, gastroparesis.
Acute Kidney Injury and Impairment of Renal Function Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring bydureon package insert and kidney transplantation have been reported.
IMPORTANT SAFETY INFORMATION
Gastrointestinal Disease Because exenatide is commonly associated with gastrointestinal adverse reactions, not recommended in patients with severe gastrointestinal disease eg, gastroparesis. Hypersensitivity Reports of serious hypersensitivity reactions eg, anaphylaxis and angioedema. After initiation, observe patients carefully for symptoms of pancreatitis.
Exenatide bydureon package insert weekly improved hour glucose control and reduced glycaemic variability in metformin-treated bydureon package insert with type 2 diabetes: Acute Kidney Injury and Impairment bydureon package insert Renal Function Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation have been reported.
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes DURATION Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls.
Should not be used to treat type 1 diabetes or diabetic ketoacidosis. Hypoglycemia Risk of hypoglycemia is increased when exenatide is coadministered with insulin or insulin secretagogues. Any reference in these archives to AstraZeneca bydureon package insert or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data bydkreon safety data.